Jesy Nelson Reveals Twin Daughters' SMA Type 1 Diagnosis
Former Little Mix star Jesy Nelson has publicly disclosed that her twin daughters, Ocean Jade and Story Monroe Nelson-Foster, have been diagnosed with Spinal Muscular Atrophy (SMA) Type 1. This rare genetic condition is severe and may prevent the children from ever walking. The 34-year-old singer, who welcomed the twins prematurely in May 2025 with partner Zion Foster, shared this emotional news in an Instagram video last year, detailing a gruelling three to four months of medical appointments that led to the diagnosis.
Campaign for Newborn Screening Gains Momentum
Nelson has since launched a campaign advocating for SMA Type 1 to be included in the newborn blood spot screening test, commonly known as the heel prick test. In a heartfelt conversation on ITV's This Morning with Health Secretary Wes Streeting, she expressed frustration, stating, "It's just madness to me that we are living in a day and age now where we have got three treatments that are life changing, and it's still not part of the heel prick test." She warned that without this screening, many more families could face similar hardships unnecessarily.
Heartbreaking Prognosis and Medical Journey
Recalling the prognosis from Great Ormond Street Hospital, Nelson shared the devastating reality that her daughters might never walk or regain neck strength, leading to lifelong disabilities. She expressed profound gratitude that treatment is available, noting, "if they don't have it, they will die," but described the hospital as her "second home" due to the relentless medical care required.
Understanding Spinal Muscular Atrophy
To provide clarity on SMA, Giles Lomax, CEO of Spinal Muscular Atrophy UK, explained that it is a rare neuromuscular condition affecting approximately one in 14,000 births annually. It involves the loss of motor function across the body due to faulty SMN1 genes, with a one in four chance of inheritance from parents. There are four primary types:
- Type 1: The most severe, appearing in babies under six months, characterized by floppiness, breathing difficulties, and inability to sit.
- Type 2: Emerges between six and 17 months, allowing sitting but not walking, with potential scoliosis.
- Type 3: Diagnosed in older children who may lose walking ability after age three.
- Type 4: The rarest, developing in adulthood, often milder but challenging to diagnose.
Key Symptoms and Diagnosis
Lomax highlighted critical signs of SMA Type 1, including floppiness, difficulty lifting the head or feeding, belly breathing, and abnormally low muscle tone in limbs. Diagnosis is confirmed through a blood test for the SMN1 gene. Early detection is crucial, as Lomax emphasized that with prompt treatment, many children can follow normal development pathways. Without intervention, survival past age two is unlikely for Type 1 cases.
Daily Challenges and Available Treatments
Living with SMA involves significant health challenges, such as weakened respiratory muscles leading to frequent infections and hospital stays. Daily life requires extensive medical support, including occupational therapy, physiotherapy, neurology appointments, and equipment like wheelchairs and respiratory aids. Fortunately, three disease-modifying therapies are available in the UK:
- Zolgensma: A one-time infusion gene therapy for babies under 12 months.
- Risdiplam: An oral medication taken daily for life, suitable from infancy to adulthood.
- Nusinersen: An injection into the spinal cord required every three to four months for life.
A Beacon of Hope Amidst Adversity
Jesy Nelson's candid revelation sheds light on the profound struggles faced by families dealing with SMA. While the journey for Ocean Jade and Story Monroe will be arduous, the availability of effective therapies offers hope, potentially transforming outcomes for children with this severe condition. Her advocacy underscores the urgent need for broader newborn screening to prevent future diagnoses and support early intervention.
